ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company s lead product candidate, Gencaro, is a pharmacologically unique beta-blocker and mild vasodilator that is being developed for the treatment of atrial fibrillation in patients with heart failure. The company has a commercialization and licensing agreement with Laboratory Corporation of America to develop, make, market, and sell diagnostic tests in connection with the medical prescription of Gencaro; and a collaboration agreement with Archemix Corporation for the discovery and development of novel aptamers with anti-coagulation activities. ARCA biopharma, Inc. is headquartered in Broomfield, Colorado.
Symbol:
Current Quote
last: 2.34
bid:
ask:
volume: 73901

as of (GMT): 2013-05-20 15:59:00
*Quotes delayed by 20min.
Stock Exchange / Market : Pink
 Listed 4 consecutive market days. On list 02/07/2012 through 02/13/2012 

3 Month
ABIO 3 Month

6 Month
ABIO 6 Month

1 Year
ABIO 1 Year

Borrow Rates (per share)